Literature DB >> 16885624

Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapy.

Mariana Guerrero1, X Allen Li.   

Abstract

The halftime for repair of sub-lethal damage is an important radiobiological parameter in analysing radiation responses and in designing new treatments involving different dose rates. This work is to resolve an inconsistency existing in the repair halftime for the bladder and rectum, two of the most dose limiting critical structures for pelvic irradiation. Both long (1.5-2 h) and short (0.3-1 h) repair halftimes have been reported previously. In this work, by reconciling clinical data from cervical brachytherapy of different dose rates and by introducing a sparing factor to consider the dose sparing occurring for critical structures, we have estimated that the most likely value of the repair halftime for bladder and rectum is short, 0.2-0.4 h if assuming alpha/beta = 2-4 Gy. The present analysis does not support the long repair halftimes reported previously for the bladder and rectum and for other normal structures.

Mesh:

Year:  2006        PMID: 16885624     DOI: 10.1088/0031-9155/51/16/012

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  9 in total

1.  Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer.

Authors:  Trinitat García Hernández; Aurora Vicedo González; Jorge Pastor Peidro; Juan V Roselló Ferrando; Luis Brualla González; Domingo Granero Cabañero; José López Torrecilla
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-08

2.  Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes".

Authors:  T S A Underwood; R G Dale; A M Bidmead; C A Nalder; P R Blake
Journal:  Br J Radiol       Date:  2011-01-25       Impact factor: 3.039

3.  Ku-dependent non-homologous end-joining as the major pathway contributes to sublethal damage repair in mammalian cells.

Authors:  Min Liu; Solah Lee; Bailong Liu; Hongyan Wang; Lihua Dong; Ya Wang
Journal:  Int J Radiat Biol       Date:  2015-08-27       Impact factor: 2.694

Review 4.  Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.

Authors:  Víctor Macías; Albert Biete
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

5.  Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy.

Authors:  V Macias; R Gonzalez Celador; C Marti-Macia; C Cigarral; L A Perez-Romasanta
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

6.  Biological effective dose evaluation in gynaecological brachytherapy: LDR and HDR treatments, dependence on radiobiological parameters, and treatment optimisation.

Authors:  C Bianchi; F Botta; L Conte; P Vanoli; L Cerizza
Journal:  Radiol Med       Date:  2008-07-10       Impact factor: 3.469

7.  Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

Authors:  S Lucas; O Feron; B Gallez; B Masereel; C Michiels; T Vander Borght
Journal:  Comput Math Methods Med       Date:  2015-06-02       Impact factor: 2.238

8.  Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion.

Authors:  Honglai Zhang; Lin Wang; Adam C Riegel; Jeffrey Antone; Louis Potters; Lucille Lee; Yijian Cao
Journal:  J Appl Clin Med Phys       Date:  2022-03-14       Impact factor: 2.243

9.  Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy.

Authors:  Jakub Pritz; Kenneth M Forster; Amarjit S Saini; Matthew C Biagioli; Geoffrey G Zhang
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.